0
0
January 19, 2026
BOSTON — Researchers at the Boston University Chobanian & Avedisian School of Medicine have identified a promising new pathway for treating Alcohol Use Disorder (AUD), discovering that a specific class of medication currently used for ADHD can significantly reduce heavy drinking and repair cognitive deficits. The study, published this week in the journal eNeuro, suggests that the drug guanfacine may offer a safer, more targeted alternative to existing treatments by stabilizing the brain’s stress response system without the debilitating side effects of older medications.
The Search for a Better Balance
Alcohol Use Disorder remains one of the most pressing public health crises in the United States, affecting approximately 29 million individuals and contributing to over 140,000 deaths annually. Despite these staggering numbers, the medical toolkit for treating AUD is remarkably limited.
Current FDA-approved medications work for some, but many patients find them only modestly effective or struggle with side effects. Furthermore, chronic alcohol use often damages the “executive suite” of the brain—the prefrontal cortex—leading to struggles with memory, attention, and the ability to switch between tasks. These cognitive hurdles often make the path to recovery feel insurmountable.
“We are looking for treatments that not only reduce the urge to drink but also help restore the brain functions that allow a person to maintain control over their life,” says Pietro Cottone, Ph.D., associate professor at Boston University and co-corresponding author of the study.
Target: The Norepinephrine System
The research focused on the brain’s norepinephrine system, which governs the body’s “fight or flight” stress response. Chronic, heavy drinking essentially “breaks” this thermostat, leaving norepinephrine-producing centers in the brain chronically overactive. This state of constant chemical stress drives the compulsion to drink and clouds judgment.
To address this, the team tested Alpha-2 adrenergic agonists, drugs designed to stimulate receptors that act as a “brake” on the norepinephrine system. They compared two specific medications:
-
Clonidine: An older medication used for high pressure and anxiety.
-
Guanfacine: A more selective drug currently FDA-approved for ADHD.
While both drugs reduced alcohol intake in experimental models, clonidine came with a heavy price: it caused significant sedation and dangerous drops in body temperature. Guanfacine, however, reduced heavy drinking without these adverse effects.
Crucially, guanfacine did not stop the subjects from enjoying other liquids or sweets, suggesting it specifically targets the drive for alcohol rather than numbing the brain’s general ability to feel pleasure—a common complaint with some existing addiction treatments.
Beyond Sobriety: Healing the Mind
Perhaps the most encouraging finding involves “executive function.” During the acute withdrawal phase—a time when many people are most vulnerable to relapse—guanfacine improved performance on memory tasks associated with the prefrontal cortex.
“Alcohol addiction dysregulates norepinephrine systems,” the researchers noted. By selectively stimulating Alpha-2 receptors, guanfacine appeared to restore balance, reducing the drive to drink while simultaneously sharpening the cognitive tools needed to resist cravings.
“Because guanfacine is already approved for other uses, this work could accelerate clinical testing compared with developing a brand-new drug,” explains co-corresponding author Valentina Sabino, Ph.D.
Expert Perspective and Limitations
While the results are a significant milestone, independent experts urge cautious optimism.
“Repurposing existing medications is a brilliant strategy for speeding up the delivery of care to patients,” says Dr. Elena Rossi, a clinical addiction specialist not involved in the study. “However, we must remember that mouse models, while highly predictive of brain chemistry, do not account for the complex social and psychological layers of human addiction. We need robust human clinical trials to confirm these safety and efficacy profiles.”
The study also noted that while executive function (decision-making and memory) improved, spatial memory did not show the same gains, suggesting that the drug’s cognitive benefits may be highly specialized.
What This Means for Patients
For those currently struggling with AUD, this study does not mean you should seek a guanfacine prescription today. It does, however, signal a shift in how science approaches the “brain fog” associated with recovery.
If future human trials mirror these results, physicians may soon have a tool that addresses two problems at once: the physical craving for alcohol and the cognitive impairment that so often leads to relapse.
References
Primary Study:
-
Quadir, S. G., et al. (2026). “Alpha-2 Adrenergic Agonists Reduce Heavy Alcohol Drinking and Improve Cognitive Performance in Mice.” eNeuro. DOI: 10.1523/eneuro.0368-25.2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
